BioXcel Therapeutics, Inc. (BTAI)
Chart Events
Performance Outlook
| Previous Close | 2.8400 |
| Open | 2.8500 |
| Bid | 2.9500 x 800 |
| Ask | 2.9600 x 800 |
| Day's Range | 2.8100 - 3.0000 |
| 52 Week Range | 2.8050 - 34.1250 |
| Volume | |
| Avg. Volume | 3,046,923 |
| Market Cap | 86.335M |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.8700 |
| Earnings Date | Nov 08, 2023 - Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BTAI
Related Research
- BioXcel Therapeutics, Inc.Analyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.RatingFair ValueEconomic Moat5 days agoArgus Research
Insider Monkey16 Most Shorted Stocks Right Now
In this piece, we will take a look at the 16 most shorted stocks right now. If you want to skip our introduction to short selling, then take a look at 5 Most Shorted Stocks Right Now. One of the most intriguing plays on the stock market is short selling. This is because it goes […]
- Zacks Small Cap Research
BTAI: Strategic Reprioritization Underway...
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Strategic Reprioritization Underway On August 14, 2023, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced a strategic reprioritization that will impact a number of the areas of the business, including: • The commercial strategy for IGALMI will shift to focus more on the retail pharmacy and at-home setting and away
Motley FoolWhy BioXcel Therapeutics Stock Flopped Again Today
After the biotech's share price tanked on Monday on the back of less-than-inspiring quarterly results and the announcement of significant job cuts, it was hammered again the following day. As often happens in the wake of quarterly earnings reports that are either far better or substantially worse than expected, analysts adjusted their takes on BioXcel Tuesday. One prognosticator, Graig Suvannavejh of Mizuho Securities, went as far as to downgrade his recommendation on the stock.
